• 1
    Haug C, Schmid-Kotsas A, Zorn U, et al. Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocytederived macrophages is up-regulated by low density lipoproteins. J Mol Cell Cardiol. 2001;33:17011712.
  • 2
    Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:14501457.
  • 3
    Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39:10201025.
  • 4
    Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension. 2007;49:792798.
  • 5
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:112.
  • 6
    Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135:982989.
  • 7
    Lavallée PC, Labreuche J, Gongora-Rivera F, et al. Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease. Stroke. 2009;40:17211728.
  • 8
    Mancia G, Parati G, Revera M, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ. 2010;340:c1197.
  • 9
    Manisty C, Mayet J, Tapp RJ, et al. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension. 2009;54:10091013.
  • 10
    Williams B, Lacy PS, Cruickshank JK, et al. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation. 2009;119:5361.
  • 11
    Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension. 2009;54:763768.
  • 12
    Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011;146:319325.
  • 13
    Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008;168:721727.
  • 14
    Grimm R, Malik M, Yunis C, et al.; TOGETHER Investigators. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc Health Risk Manag. 2010;6:261271.
  • 15
    Balletshofer BM, Goebbel S, Rittig K, et al. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes–a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes. 2005;113:324330.
  • 16
    Kuklinska AM, Mroczko B, Musial WJ, et al. Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients—An open, pilot study. Blood Press. 2010;19:260266.
  • 17
    Spósito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83:14971499.
  • 18
    Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol. 2005;46:310315.
  • 19
    Tonelli M, Sacks F, Pfeffer M, et al. Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens. 2006;20:560565.
  • 20
    Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens. 2009;27:947954.
  • 21
    Teixeira AA, Buffani A, Tavares A, et al. Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients. J Hum Hypertens. 2011;25:492499.
  • 22
    Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004;18:781788.
  • 23
    Borghi C, Dormi A, Veronesi M, et al; Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J. 2004;148:285292.
  • 24
    Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens. 2004;17:823827.
  • 25
    Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol. 2001;21:449454.
  • 26
    Bak AA, Huizer J, Leijten PA, et al. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. J Intern Med. 1998;244:371378.
  • 27
    Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, doubleblind, placebo-controlled comparison of the action of orlistat, fluvastatin or both, on anthropometric measurements, blood pressure and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther. 2003;25:11071122.
  • 28
    Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2_ formation. J Cardiovasc Pharmacol. 2002;40:868874.
  • 29
    McDowell IF, Smye M, Trinick T, et al. Simvastatin in severe hypercholesterolaemia: a placebo controlled trial. Br J Clin Pharmacol. 1991;31:340343.
  • 30
    Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447451.
  • 31
    Kanaki AI, Sarafidis PA, Georgianos PI, et al. Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study. J Hum Hypertens. 2011;26:577584 doi: 10.1038/jhh.2011.80.
  • 32
    Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151:273281.
  • 33
    Sever PS, Dahlof B, Poulter NR, et al., on behalf of the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:11491158.
  • 34
    Cohn JN, Wilson DJ, Neutel J, et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens. 2009;22:137144.
  • 35
    Danaoğlu Z, Kültürsay H, Kayikçioğlu M, et al. Effect of statin therapy added to ACE-inhibitors on blood pressure control and endothelial functions in normolipidemic hypertensive patients. Anadolu Kardiyol Derg. 2003;3:331337.
  • 36
    Fassett RG, Robertson IK, Ball MJ, et al. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J Atheroscler Thromb. 2010;17:235241.
  • 37
    Ge CJ, Lu SZ, Chen YD, et al. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels. 2008;23:9195.
  • 38
    Hjelstuen A, Anderssen SA, Holme I, et al. Effect of lifestyle and/or statin treatment on soluble markers of atherosclerosis in hypertensives. Scand Cardiovasc J. 2007;41:313320.
  • 39
    Ichihara A, Hayashi M, Koura Y, et al. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19:103109.
  • 40
    Kushiro T, Mizuno K, Nakaya N, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension. 2009;53:135141.
  • 41
    Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:12811286.
  • 42
    Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond). 2009;116:497505.
  • 43
    Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J. 2004;6:742746.
  • 44
    Olkinuora JT, Viikari J, Vanhanen H, et al. Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study). Scand Cardiovasc J. 2006;40:160166.
  • 45
    Lewandowski J, Siński M, Bidiuk J, et al. Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res. 2010;33:10381043.
  • 46
    Su SF, Hsiao CL, Chu CW, et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol. 2000;86:514518.
  • 47
    Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997;20:18911895.
  • 48
    Hodis HN, Blankenhorn DH, Azen SP, et al; MARS Research Group. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969976.
  • 49
    Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757767.
  • 50
    Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335345.
  • 51
    Sun W, Lee TS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation. 2006;114:26552662.
  • 52
    Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:2426624271.
  • 53
    Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension. 2007;50:377383.